Pacira BioSciences SVP Lauren Riker sells $217,920 in stock

Lauren Riker, Senior Vice President of Finance at Pacira BioSciences, sold 6,000 shares of the company's common stock for a total of $217,920 on October 8, 2026. She exercised options to acquire 6,000 shares at $32.35 per share, totaling $194,100. These shares were then sold at $36.32 each. The sale occurred as the stock traded near its 52-week high of $36.46, following a 44% gain over a week and a 62% return over the past year.

Both actions followed a Rule 10b5-1 trading plan, adopted by Ms. Riker on March 12, 2026. The stock option vested over time, with 25% becoming exercisable after a year and the rest in quarterly installments over three years. Following the transactions, Ms. Riker holds 62,284.242 shares of Pacira BioSciences common stock. The stock is currently considered undervalued, with a Piotroski Score of 9, indicating strong financial health.

Pacira BioSciences reported a 6% revenue increase in Q2, reaching $192.4 million, surpassing expectations. Viatris acquired Pacira Pharmaceuticals for $1.65 billion, leading to a downgrade of the stock rating to 'Hold' by Jefferies. Oppenheimer initiated coverage with an 'outperform' rating and a price target of $32.00.